THERALINK TECHNOLOGIES, INC.
Healthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $606,796 | $567,905 | $505,604 | $181,229 | — | — |
| Operating income | −$9.0M | −$11.6M | −$5.6M | −$3.4M | −$1.5M | −$1.8M |
| Net income | −$30.9M | −$12.7M | −$5.5M | −$3.2M | −$1.6M | $6.5M |
| Total assets | $2.8M | $2.6M | $1.6M | $3.2M | $1.1M | $226,586 |
| Total liabilities | $41.0M | $6.4M | $3.6M | $1.5M | $1.7M | $7.8M |
| Equity | −$38.1M | −$6.8M | −$4.9M | −$307,595 | −$632,360 | −$812,545 |
| EPS (diluted) | $-0.01 | $0.00 | $0.00 | — | $-19.00 | $9.09 |
| Shares out. | 6.15B | 6.15B | 5.56B | 881,118 | 285.4M | 223.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −1479.8%
- Net margin
- −5093.6%
- Return on equity
- 81.1%
- Return on assets
- −1084.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 1437.5%
- Debt / equity
- —
- Book value / share
- $-0.01
- Revenue growth (YoY)
- 6.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -218.19distress
- Accruals / assets
- −881.9%clean
- Beneish M-Score
- -45.74normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Feb 15, 2024
- NT 10-Kmissed a reporting deadline ↗Dec 29, 2023
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
- NT 10-Qmissed a reporting deadline ↗Feb 15, 2023
- NT 10-Qmissed a reporting deadline ↗May 17, 2022
- NT 10-Qmissed a reporting deadline ↗Feb 15, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Kucharchuk Andrew AlbertOfficer — CEO and CFO | May 7, 2020 | Grant | 283,334 | $0.06 |
| Head Jonathan FrederickDirector | May 7, 2020 | Grant | 166,667 | $0.06 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Debt acceleration / triggering eventMar 6, 2024
- Other material eventNov 28, 2023
- Director / officer change · Regulation FD disclosureJun 29, 2023
- Entered a material agreement · Other material eventMay 26, 2023
- Director / officer changeMay 11, 2023
- Entered a material agreement · New financial obligation · Unregistered equity saleFeb 1, 2023
- Director / officer change · Regulation FD disclosureDec 9, 2022
- Entered a material agreement · New financial obligation · Unregistered equity sale · Other material eventDec 1, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.